1.64 0.00 (0.00%)
After hours: 5:10PM EDT
|Bid||1.64 x 2200|
|Ask||1.70 x 1100|
|Day's Range||1.59 - 1.66|
|52 Week Range||0.65 - 8.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 31, 2017 - Nov 6, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.00|
On a per-share basis, the High Point, North Carolina-based company said it had a loss of 30 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...
vTv Therapeutics Inc. today reported financial and operational results for the first quarter that ended March 31, 2018.
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / vTv Therapeutics and ARCA biopharma were both soaring in Thursday's trading session. Both had news as catalysts to drive shares higher with vTv Therapeutics announcing ...
vTv Therapeutics Inc. (VTVT) today announced that based on post-hoc analyses of the data from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease, despite not meeting co-primary endpoints, identified a subpopulation that showed statistically significant benefit (unadjusted for multiple, post hoc comparisons) from azeliragon relative to placebo on ADAS-cog. Based on the subpopulation data analyses from the Part A study and the prior azeliragon trials, the company will submit a revised Statistical Analysis Plan (SAP) to the Food and Drug Administration for the Part B Study that pre-specifies a target population for the primary study analysis and expects to report Part B topline efficacy results based on 12 month data in June 2018.
The executive is leaving about three weeks after the clinical stage pharmaceutical company announced disappointing trial results for one of its key drug prospects that was aimed at Alzheimer's.
Shares of InVivo also headed higher after a reverse stock split this week. InVivo is also in the process of finalizing a lease assignment that the company expects will result in lease-related savings of approximately $3M through 2019.
The prospect of vTv Therapeutics moving its office was raised after it was revealed Cambrex Corp. bought the building. The company is also ending clinical trials for an Alzheimer's drug it has been developing.
It's the first day the stock hit above $1 since vTv Therapeutics reported disappointing results from the Phase 3 study of its drug azeliragon.
Cambrex has taken steps toward another expansion by buying up two buildings for $10.2 million.
vTv Therapeutics (VTVT) shares suffered a major blow when the company's late stage study on lead candidate, azeliragon, for the treatment of Alzheimer's failed.
vTv Therapeutics Inc (NASDAQ: VTVT ) announced Monday after the close that results from Part A of its late-stage study of an investigational medication to treat Alzheimer's disease did not meet either ...
Shares of vTv Therapeutics Inc. plunged in the extended session Monday after the drug developer said a late-stage clinical trial of its Alzheimer's disease treatment did not meet study goals. Shares of ...
vTv Therapeutics, Inc. today announced that results from Part A of the Company’s Phase 3 STEADFAST study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet either co-primary efficacy endpoint.
Stock Monitor: BioLine Rx Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 27, 2018 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT ). If you ...
The study is underway through a partnership with JDRF, with both of the companies putting up $3 million each for the assessment.
vTv Therapeutics Inc. today announced the completion of Phase 1b of Simplici-T1, an adaptive Phase 1b/2 study assessing the pharmacokinetics, pharmacodynamics, safety and tolerability of TTP399 in adult patients with type 1 diabetes .
vTv Therapeutics Inc (NASDAQ: VTVT ) shares have outperformed Axovant Sciences Ltd (NASDAQ: AXON ) shares by 63 percent since Chardan recommended owning the former over the latter in January 2016. The ...
On a per-share basis, the High Point, North Carolina-based company said it had a loss of 44 cents. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by ...
vTv Therapeutics Inc. today provided a corporate update and reported financial and operational results for the fourth quarter and full year that ended December 31, 2017.
A bevy of biotechs led the charge in 2017 as U.S. stock markets rocketed to record highs, although analysts caution the surge had more to do with individual companies beating expectations than it did with a broader confidence in the life sciences sector as a whole. The Business Journals analysis included 3,000 publicly traded companies with at least $100 million in stock market value apiece as of Dec. 31, 2017. In the Triad, trucking and manufacturing companies had the top stocks of 2017.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to vTv Therapeutics, Inc. Here are 5 ETFs with the largest exposure to VTVT-US. Comparing the performance and risk of vTv Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
LONDON, UK / ACCESSWIRE / December 26, 2017 / Active-Investors.com has just released a free research report on vTv Therapeutics Inc. (NASDAQ: VTVT ). If you want access to this report all you need to do ...
The exact financial terms of the deal were not disclosed, but vTv Therapeutics (VTV) will receive an upfront payment and will be able to receive future development and commercialization payments as well as royalties from the sales of products. The company will also receive shares of Reneo Pharmaceuticals’ common stock. It’s the second such deal vTv Therapeutics, a biopharmaceutical firm based in High Point, has announced this week.